These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30799530)

  • 1. The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review.
    Bettiol A; Silvestri E; Di Scala G; Amedei A; Becatti M; Fiorillo C; Lopalco G; Salvarani C; Cantarini L; Soriano A; Emmi G
    Rheumatol Int; 2019 Jun; 39(6):971-990. PubMed ID: 30799530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study.
    Emmi G; Talarico R; Lopalco G; Cimaz R; Cantini F; Viapiana O; Olivieri I; Goldoni M; Vitale A; Silvestri E; Prisco D; Lapadula G; Galeazzi M; Iannone F; Cantarini L
    Clin Rheumatol; 2016 May; 35(5):1281-6. PubMed ID: 26156661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
    Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Currently Used Biologic Agents in the Management of Behcet's Syndrome.
    Saygin C; Uzunaslan D; Hatemi G
    Curr Med Chem; 2015; 22(16):1976-85. PubMed ID: 25666786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease.
    Cantarini L; Lopalco G; Caso F; Costa L; Iannone F; Lapadula G; Anelli MG; Franceschini R; Menicacci C; Galeazzi M; Selmi C; Rigante D
    Autoimmun Rev; 2015 Jan; 14(1):1-9. PubMed ID: 25151975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.
    Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH
    Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection.
    Emmi G; Silvestri E; Squatrito D; Vitale A; Bacherini D; Vannozzi L; Emmi L; D'Elios MM; Cantarini L; Prisco D
    Int J Dermatol; 2017 Feb; 56(2):218-220. PubMed ID: 27336860
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study.
    Di Scala G; Bettiol A; Cojan RD; Finocchi M; Silvestri E; Emmi G
    J Autoimmun; 2019 Feb; 97():108-113. PubMed ID: 30213443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Gevokizumab in Patients with Behçet's Disease Uveitis: Results of an Exploratory Phase 2 Study.
    Tugal-Tutkun I; Kadayifcilar S; Khairallah M; Lee SC; Ozdal P; Özyazgan Y; Song JH; Yu HG; Lehner V; de Cordoue A; Bernard O; Gül A
    Ocul Immunol Inflamm; 2017 Feb; 25(1):62-70. PubMed ID: 26829647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.
    Vieira M; Buffier S; Vautier M; Le Joncour A; Jamilloux Y; Gerfaud-Valentin M; Bouillet L; Lazaro E; Barete S; Misery L; Gobert D; Goulenok T; Fain O; Sacre K; Sève P; Cacoub P; Comarmond C; Saadoun D
    Front Immunol; 2020; 11():626792. PubMed ID: 33613571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cytokine biologic treatment beyond anti-TNF in Behçet's disease.
    Arida A; Sfikakis PP
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S149-55. PubMed ID: 25268669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease.
    Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Di Scala G; Sota J; Orlando I; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Ocul Immunol Inflamm; 2020; 28(2):298-304. PubMed ID: 30148652
    [No Abstract]   [Full Text] [Related]  

  • 13. Interleukin-1 Inhibition in Behçet's disease.
    Vitale A; Rigante D; Lopalco G; Selmi C; Galeazzi M; Iannone F; Cantarini L
    Isr Med Assoc J; 2016; 18(3-4):171-6. PubMed ID: 27228638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating the Different Phenotypes of Behçet's Syndrome.
    Bettiol A; Hatemi G; Vannozzi L; Barilaro A; Prisco D; Emmi G
    Front Immunol; 2019; 10():2830. PubMed ID: 31921115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Behçet's disease.
    Alibaz-Oner F; Sawalha AH; Direskeneli H
    Curr Opin Rheumatol; 2018 May; 30(3):238-242. PubMed ID: 29432223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anakinra treatment in drug-resistant Behcet's disease: a case series.
    Cantarini L; Vitale A; Scalini P; Dinarello CA; Rigante D; Franceschini R; Simonini G; Borsari G; Caso F; Lucherini OM; Frediani B; Bertoldi I; Punzi L; Galeazzi M; Cimaz R
    Clin Rheumatol; 2015 Jul; 34(7):1293-301. PubMed ID: 24305945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply: anti-IL1 blocking agents in drug-resistant Behçet's syndrome: our little case series.
    Emmi G; Silvestri E; Ciucciarelli L; Squatrito D; Emmi L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S172. PubMed ID: 24709082
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of Gevokizumab in Patients with Behçet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study.
    Tugal-Tutkun I; Pavesio C; De Cordoue A; Bernard-Poenaru O; Gül A
    Ocul Immunol Inflamm; 2018; 26(7):1023-1033. PubMed ID: 29370572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study.
    Sota J; Vitale A; Insalaco A; Sfriso P; Lopalco G; Emmi G; Cattalini M; Manna R; Cimaz R; Priori R; Talarico R; de Marchi G; Frassi M; Gallizzi R; Soriano A; Alessio M; Cammelli D; Maggio MC; Gentileschi S; Marcolongo R; La Torre F; Fabiani C; Colafrancesco S; Ricci F; Galozzi P; Viapiana O; Verrecchia E; Pardeo M; Cerrito L; Cavallaro E; Olivieri AN; Paolazzi G; Vitiello G; Maier A; Silvestri E; Stagnaro C; Valesini G; Mosca M; de Vita S; Tincani A; Lapadula G; Frediani B; De Benedetti F; Iannone F; Punzi L; Salvarani C; Galeazzi M; Angotti R; Messina M; Tosi GM; Rigante D; Cantarini L;
    Clin Rheumatol; 2018 Aug; 37(8):2233-2240. PubMed ID: 29770930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic solutions for Behçet's syndrome.
    Vitale A; Rigante D; Lopalco G; Emmi G; Bianco MT; Galeazzi M; Iannone F; Cantarini L
    Expert Opin Investig Drugs; 2016 Jul; 25(7):827-40. PubMed ID: 27163156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.